Quantum Genomics announces that it has obtained the approval of the General Meeting of Shareholders for the reduction of its share capital and the contribution in kind of 100% of ExactCure's shares.
Le projet EFFI-CLIN, dont la société HISTALIM est partenaire, vise à proposer une nouvelle immunothérapie du cancer adaptée au profil immunologique de chaque tumeur selon le concept de la médecine personnalisée en ciblant une nouvelle génération de checkpoints immunitaires.
Do you accept the deposit and reading of cookies in order to allow us to analyze your browsing anonymously and measure the audience of our website?YesNoPrivacy policy
You can revoke your consent at any time by using the "Revoke consent" button.Revoke consent